ALB shorts rebuild as earnings loom in four days

Albemarle fell 2.9% this week to $91.00, a smaller drop than the median 4.2% decline across its closest peers, yet the more telling move is under the surface: short interest climbed 5.9% in a single week to 10.3% of the free float, the highest level in six weeks.

Short positions have been rebuilding steadily through October. From a base of roughly 10.1 million shares in mid-September, shorts have added nearly two million shares, pushing the count past 12 million. The official FINRA fortnightly figure confirmed 12.25 million shares short as of October 15, with 4.95 days to cover. Despite the increased positioning, borrowing costs remain low at 0.48% and availability is loose at 509%, meaning around five shares remain available in the lending pool for every one already borrowed. The 52-week peak availability low was 305%, so the borrow market is nowhere near stressed. New shorts can enter easily and cheaply. What makes this week's rebuild notable is that it is happening into a print, not after one.

Options tell a different story from the short book. The put/call ratio has dropped to 0.89, more than a standard deviation below its 20-day average of 0.99, and is approaching the 52-week low of 0.78. Call volume has been outpacing puts for the past two weeks, a reversal from early October when the ratio was running above 1.10. That divergence, short interest climbing while the options market tilts toward calls, is the tension heading into the November 4 earnings release.

Analyst activity this month has been a one-way street of target cuts, but few outright downgrades. Citigroup trimmed its target from $175 to $125 on October 22 while holding Buy. RBC cut from $157 to $129, also holding Outperform. Barclays initiated at Equal-Weight with a $109 target. Mizuho was the outlier, upgrading to Outperform on October 14. The consensus mean target is $154.68 against a stock trading at $91, implying significant distance between where the Street thinks fair value is and where the market is pricing Albemarle today. The bull case rests on integrated, low-cost lithium assets, net leverage of just 0.5x, and $3.2 billion of liquidity. The bear case is simpler: lithium prices need to stay above marginal production costs, and they have not been cooperating. EPS momentum ranks in the 13th to 16th percentile over both 30 and 90 days, while the forward earnings growth factor ranks in the 97th percentile, an unusual combination that reflects a very depressed base rather than genuine acceleration.

Franklin Templeton filed a Schedule 13G amendment on October 28, just three days ago, disclosing its stake has grown from 3.1% to 5.0%. Capital World Investors filed in May with a 9.5% stake, up from 8.4%. BlackRock holds 8.1% per its most recent filing. These are passive or index-adjacent holders, no 13D activist is on the register, and the disclosure caveat applies: stakes are as-last-disclosed and can move below 5% without a further filing. Still, Franklin's fresh filing arriving days before earnings is the most recent ownership signal in the data.

The last earnings print, in early August, produced a 10.3% one-day gain followed by a further 9.8% rise over the following week. Closest peer SQM fell 4.4% this week, slightly worse than Albemarle's 2.9% move. The November 4 release is the next hard test: the gap between short interest rebuilding to a six-week high and the options market leaning toward calls will have an answer inside 96 hours.